Federica Lumetti
Overview
Explore the profile of Federica Lumetti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
333
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Farina A, Medico P, Parisi S, Becciolini A, Visalli E, Molica-Colella A, et al.
Mediterr J Rheumatol
. 2025 Jan;
35(4):639-644.
PMID: 39886290
Background: Psoriatic arthritis (PsA) phenotypes show different responses to the many available drugs. For a tailored medicine, it is important to choose the most effective treatment according to patients' characteristics....
2.
Cacciapaglia F, De Angelis R, Ferri C, Bajocchi G, Bellando-Randone S, Bruni C, et al.
J Rheumatol
. 2025 Jan;
PMID: 39814435
Objective: Bosentan (BOS) is approved for treating pulmonary arterial hypertension (PAH) and preventing digital ulcers (DU) in systemic sclerosis (SSc). Our study aimed to evaluate whether BOS prescribed for DU...
3.
Priora M, Becciolini A, Celletti E, Di Penta M, Lo Gullo A, Paroli M, et al.
Medicina (Kaunas)
. 2025 Jan;
60(12.
PMID: 39768862
The treatment landscape for Rheumatoid Arthritis (RA) has evolved significantly with the introduction of Janus kinase inhibitors (JAKi), such as Tofacitinib (TOFA), which offer a new therapeutic option for patients...
4.
de Pinto M, Coppi F, Spinella A, Pagnoni G, Morgante V, Macripo P, et al.
Front Cardiovasc Med
. 2024 Oct;
11:1430903.
PMID: 39469124
Introduction: Reduced TAPSE/sPAP ratio has recently emerged as a predictive parameter risk factor for PH, however its role in SSc has been poorly investigated. The aim of the study was...
5.
Lumetti F, Ariani A, Marchesoni A, Becciolini A, Giuggioli D, Sandri G
Sci Rep
. 2024 Oct;
14(1):24922.
PMID: 39438513
The availability of a number of bDMARDs with different mechanism of action increases potential treatment pathways in psoriatic arthritis (PsA). In clinical practice, following the failure of one bDMARD, it...
6.
Lo Gullo A, Parisi S, Becciolini A, Paroli M, Bravi E, Andracco R, et al.
Minerva Med
. 2024 Oct;
115(4):430-438.
PMID: 39376099
Background: Upadacitinib (UPA) is a selective, reversible Janus kinase inhibitor (JAKi) approved for the treatment of RA. However, there is still no solid evidence on the long-term efficacy of UPA...
7.
Paroli M, Becciolini A, Lo Gullo A, Parisi S, Bravi E, Andracco R, et al.
J Clin Med
. 2024 Jul;
13(13).
PMID: 38999494
The Janus kinase inhibitors (JAKi) tofacitinib (TOFA), baricitinib (BARI), upadacitinib (UPA), and filgotinib (FILGO) are effective drugs for the treatment of rheumatoid arthritis. However, the US Food and Drug Administration...
8.
Sandri G, Spinella A, Sartini S, Caselgrandi F, Schiavi M, Bettelli V, et al.
J Hand Ther
. 2024 Feb;
37(3):458-464.
PMID: 38342637
Background: Reports on hand dysfunction and rehabilitation in SSc are quite scarce in the literature and mainly focus on functional assessment tools, such as the Duruoz Hand Index and the...
9.
Riccieri V, Pellegrino G, Cipolletta E, Giuggioli D, Bajocchi G, Bellando-Randone S, et al.
J Scleroderma Relat Disord
. 2024 Feb;
9(1):38-49.
PMID: 38333531
Background: Intravenous iloprost has been widely used for the treatment of systemic sclerosis peripheral vasculopathy. No agreement has been found on the regimen and the dosage of intravenous iloprost in...
10.
Ferri C, Raimondo V, Giuggioli D, Gragnani L, Lorini S, Dagna L, et al.
J Transl Autoimmun
. 2023 Oct;
7:100212.
PMID: 37854035
Introduction: The impact of COVID-19 pandemic represents a serious challenge for 'frail' patients' populations with inflammatory autoimmune systemic diseases such as systemic sclerosis (SSc). We investigated the prevalence and severity...